Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Bionor Pharma ASA announces warrant exercise

Bionor Pharma ASA
Posted on: 01 Dec 16

(Oslo, Norway, 23 November 2016)
Reference is made to the resolution by the EGM on 11 February 2016 to issue warrants to participants in the private placement and subsequent offering completed on 10 March 2016. The exercise price for the warrants is NOK 0.71 per share. The warrants expired on 30 November 2016. The Company received exercise of a total of 8624 warrants within the expiry of the exercise period and will accordingly proceed to issue 8,624 new shares at a subscription price of NOK 0.71 per share. The share capital of the Company will be increased by NOK 862.40 as a consequence of the warrant exercise.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Further information
Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: Cell Phone: +47 900 27 766
Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA E-mail: Cell Phone: +47 915 19 651


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire

Last updated on: 02/12/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.